SWOT Analysis
Strength: A growing awareness of nausea and its effective treatment among consumers is driving growth of this market. Also, advancement in drug delivery methods like extended release formulations makes these medicines more effective. Presence of established players with strong distribution networks further aid market growth.
Weakness: High development and regulatory costs associated with drug development is a weakness for small players in this space. Side effects of some nausea medicines reduces patient compliance.
Opportunity: Emergence of innovative drug formulations and delivery methods presents an opportunity for players. Also, a rising elderly population which is more susceptible to nausea related conditions will augment demand.
Threats: Expiry of patents opens up the market for generic competitors. Stringent regulatory processes for new drug approvals can delay market entry for players.
Key Takeaways
Global Nausea Medicine Market Demand is expected to witness high growth, exhibiting CAGR of 5.9% over the forecast period, due to increasing prevalence of nausea inducing conditions like motion sickness, gastrointestinal disorders, chemotherapy, and post-surgery effects.
Regional analysis: North America dominates the global nausea medicine market currently. This is attributed to the presence of affluent consumers and advanced healthcare infrastructure in the region. Asia Pacific is expected to be the fastest growing market owing to rising healthcare spending and increasing awareness about disease conditions treated by these medicines.
Key players: Key players operating in the nausea medicine market are GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bayer AG, Takeda Pharmaceutical Company Limited, AstraZeneca plc, Eli Lilly and Company. These players are focused on developing novel formulations to strengthen their product portfolios.
read more- https://makuv.com/anti-emetics-segment-to-fuel-the-growth-of-nausea-medicine-market/